A part-randomized study of intravenous oseltamivir in adolescents and adults

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 34, Issue 6, 2015, Pages 1181-1188

  Varkonyi I ^a   Chappey, C ^b   Giraudon, M ^c   Burleigh, L ^d  

^a Clinical Pharmacology Centre   (Hungary)

^b GENENTECH INC   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR;

ADOLESCENT; ADULT; ADVERSE EFFECTS; AGED; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMAN; INFLUENZA, HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; NOSE MUCOSA; PATHOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY; VIRUS CULTURE; VIRUS SHEDDING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BLOOD CHEMICAL ANALYSIS; CRITICAL ILLNESS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INFLUENZA, HUMAN; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NASAL MUCOSA; OSELTAMIVIR; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIRUS CULTIVATION; VIRUS SHEDDING; YOUNG ADULT;

EID: 84939964097     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-015-2338-5     Document Type: Article

References (13)

1. Lee N, Chan PK, Lui GC, Wong BC, Sin WW, Choi KW, Wong RY, Lee EL, Yeung AC, Ngai KL, Chan MC, Lai RW, Yu AW, Hui DS (2011) Complications and outcomes of pandemic 2009 influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza? J Infect Dis 203:1739–1747
2. Seasonal influenza (Flu). Influenza antiviral medications: summary for clinicians. Centers for Disease Control and Prevention (CDC). March 21, 2014. Available online at: http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm. Accessed 4 June 2014
3. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. World Health Organization (WHO). February 2010. Available online at: http://www.who.int/csr/resources/publications/swineflu/h1n1_use_antivirals_20090820/en/. Accessed 4 June 2014
4. Brennan BJ, Davies B, Cirrincione-Dall G, Morcos PN, Beryozkina A, Chappey C, Aceves Baldó P, Lennon-Chrimes S, Rayner CR (2012) Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers. Antimicrob Agents Chemother 56:4729–4737
5. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, Rode A, Kinnersley N, Ward P (2000) Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355:1845–1850
6. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG (2000) Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283:1016–1024
7. Tamiflu: EPAR – Product Information. Annex I: summary of product characteristics. Available online at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000402/WC500033106.pdf. Accessed 10 December 2014
8. Malato L, Llavador V, Marmier E, Youssef J, Balick Weber C, Rozé H, Bessede E, Fleury HJ (2011) Pandemic influenza A(H1N1) 2009: molecular characterisation and duration of viral shedding in intensive care patients in Bordeaux, south-west France, May 2009 to January 2010. Euro Surveill 16(4). pii: 19776
9. Fielding JE, Kelly HA, Mercer GN, Glass K (2014) Systematic review of influenza A(H1N1)pdm09 virus shedding: duration is affected by severity, but not age. Influenza Other Respir Viruses 8:142–150
10. Ariano RE, Sitar DS, Zelenitsky SA, Zarychanski R, Pisipati A, Ahern S, Kanji S, Rello J, Kumar A (2010) Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 182:357–363
11. Eyler RF, Heung M, Pleva M, Sowinski KM, Park PK, Napolitano LM, Mueller BA (2012) Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. Pharmacotherapy 32:1061–1069
12. Kromdijk W, Sikma MA, van den Broek MP, Beijnen JH, Huitema AD, de Lange DW (2013) Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique. Intensive Care Med 39:977–978
13. Mulla H, Peek GJ, Harvey C, Westrope C, Kidy Z, Ramaiah R (2013) Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support. Anaesth Intensive Care 41:66–73